Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Canner

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Controlled Clinical Trials|December 1, 1983
The Coronary Drug Project. Organizational structure of the studyP L Canner, J Stamler
Circulation|June 1, 1981
Implications of findings in the coronary drug project for secondary prevention trials in coronary heart disease. The coronary; drug project research groupP L Canner, M Halperin
Controlled Clinical Trials|December 1, 1983
The Coronary Drug Project. Experimental design featuresP L Canner, C R Klimt
European Journal of Clinical Pharmacology|January 1, 1991
Coronary drug project: experience with niacin. Coronary Drug Project Research GroupK G Berge, P L Canner
Clinical Pharmacology and Therapeutics|May 1, 1979
Terminating a long-term clinical trialC R Klimt, P L Canner
Circulation|December 1, 1982
High-density lipoprotein cholesterol and prognosis after myocardial infarctionK G Berge, P L Canner, A Hainline
Controlled Clinical Trials|September 1, 1989
Quality assurance and monitoring in the Hypertension Prevention Trial. Hypertension Prevention Trial Research GroupG J Prud'homme, P L Canner, J A Cutler
Controlled Clinical Trials|September 1, 1981
On the detection of outlier clinics in medical and surgical trials: II. Theoretical considerationsP L Canner, Y B Huang, C L Meinert
The New England Journal of Medicine|December 19, 1991
Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol loweringJ E Rossouw, P L Canner, S B Hulley
Controlled Clinical Trials|December 1, 1983
The Coronary Drug Project. Design of data formsG L Knatterud, S A Forman, P L Canner
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Controlled Clinical Trials|December 1, 1983
The Coronary Drug Project. Organizational structure of the studyP L Canner, J Stamler
Circulation|June 1, 1981
Implications of findings in the coronary drug project for secondary prevention trials in coronary heart disease. The coronary; drug project research groupP L Canner, M Halperin
Controlled Clinical Trials|December 1, 1983
The Coronary Drug Project. Experimental design featuresP L Canner, C R Klimt
European Journal of Clinical Pharmacology|January 1, 1991
Coronary drug project: experience with niacin. Coronary Drug Project Research GroupK G Berge, P L Canner
Clinical Pharmacology and Therapeutics|May 1, 1979
Terminating a long-term clinical trialC R Klimt, P L Canner
Circulation|December 1, 1982
High-density lipoprotein cholesterol and prognosis after myocardial infarctionK G Berge, P L Canner, A Hainline
Controlled Clinical Trials|September 1, 1989
Quality assurance and monitoring in the Hypertension Prevention Trial. Hypertension Prevention Trial Research GroupG J Prud'homme, P L Canner, J A Cutler
Controlled Clinical Trials|September 1, 1981
On the detection of outlier clinics in medical and surgical trials: II. Theoretical considerationsP L Canner, Y B Huang, C L Meinert
The New England Journal of Medicine|December 19, 1991
Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol loweringJ E Rossouw, P L Canner, S B Hulley
Controlled Clinical Trials|December 1, 1983
The Coronary Drug Project. Design of data formsG L Knatterud, S A Forman, P L Canner
Pageof 3